Skip to main content
Premium Trial:

Request an Annual Quote

New York Conditionally Approves Rosetta Genomics' Kidney Cancer Test

NEW YORK (GenomeWeb News) – Rosetta Genomics today said that the New York State Department of Health has given conditional approval for the company's Rosetta Kidney Cancer Test for patient samples originating from New York.

As a result of the conditional approval, the test is now available in all 50 states in the US. However, Rosetta will have to provide any additional information within 60 business days to NYDOH as requested as part of the conditional approval, the Israel-based developer of microRNA-based molecular diagnostics tests said.

Citing figures from the American Cancer Society, Rosetta said that kidney cancer is one of the 10 most common cancers and will account for 65,000 new cases and 14,000 deaths in the US in 2013. Its test classifies the four most common kidney tumors — clear cell renal cell carcinoma (RCC); papillary RCC; chromophobe RCC; and the benign oncocytoma.

The test is sold through Rosetta's CLIA laboratory in Philadelphia.